Replies to post #80530 on Biotech Values

[jbog]

Dew,

"""Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN ), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases

Are there any rules that would classify any given company as an "leader" versus an "follower" or maybe an "also ran"???

[mcbio]

Re: ACHN SEDA

Good points regarding the release. If this was truly done because the company believes this will increase their bargaining power at the negotiation table for ACH-1625 (or any of the other non-HCV compounds), then by all means I'm all for it. ACHN did indicate that they have sufficient resources for the coming year and that they don't intend to draw on the facility, which is good. If they release positive results for ACH-1625 around year-end, I would expect they would be able to garner a nice partnership and upfront milestone and would clearly not need this credit facility.

ACHN is effectively all about ACH-1625 these days and is really a boom or bust proposition, which makes me a bit nervous. However, I'm holding my entire position at least until the Phase 1 results are released. Besides, surely my MNTA and IDIX holdings will offset any potential losses from ACHN. ; )